Osimertinib in Japanese patients with EGFR T790M mutation‐positive advanced non‐small‐cell lung cancer: AURA3 trial

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the first‐line treatment for patients with EGFR mutant non‐small‐cell lung cancer (NSCLC). However, most patients become resistant to these drugs, so their disease progresses. Osimertinib, a third‐generation EGFR‐TKI that...

Descripción completa

Detalles Bibliográficos
Autores principales: Akamatsu, Hiroaki, Katakami, Nobuyuki, Okamoto, Isamu, Kato, Terufumi, Kim, Young Hak, Imamura, Fumio, Shinkai, Masaharu, Hodge, Rachel A., Uchida, Hirohiko, Hida, Toyoaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989837/
https://www.ncbi.nlm.nih.gov/pubmed/29697876
http://dx.doi.org/10.1111/cas.13623

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989837/
https://www.ncbi.nlm.nih.gov/pubmed/29697876
http://dx.doi.org/10.1111/cas.13623

Ejemplares similares